European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows posit ...
July 25, 2024 — A new study brings researchers closer to better understanding the pathology of the fatty liver disease MASH, which stands for metabolic dysfunction-associated steatohepatitis.
Liver biopsy exhibited chronic intrahepatic cholestasis, with transition into ... with cholestyramine can affect the course of the disease is unknown. It seems clear that agents with bile-acid ...